61results about How to "Avoid overtreatment" patented technology

The invention provides systems and method for the removal of diseased cells during surgery.

A system and method for managing a herd of animals possibly requiring medical treatment, such as cows in a feedlot. The animals are herded individually into a chute, where identification data is collected from a tag, and core temperature data is collected using a special non-contacting core temperature sensor. The animal is tagged with a color coded tag representing a range of temperatures into which that animal's temperature falls. The animal is then delivered to a pen corresponding to that range of temperatures, where appropriate medicinal treatment is automatically dosed and applied to the animal.

A flexible sleeve mountable to an endoscope having a proximal portion, a distal portion, a first channel dimensioned to receive an endoscope, and a second channel dimensioned to receive an electrode. The electrode is slidable within the second channel from a retracted position wherein a tip of the electrode is unexposed from the sleeve and an extended position wherein the tip of the electrode is exposed from the sleeve and curves toward target tissue.

The invention relates to a kit for early screening and diagnosis of prostate cancer. The kit comprises upstream and downstream primers of at least two genes of ITGB5, TMEM176B and TMP1, wherein an ITGB5 primer pair is as shown in SEQ ID NO:1 and SEQ ID NO:2; a TMEM176B primer pair is as shown in SEQ ID NO:3 and SEQ ID NO:4; a TIMP1 primer pair is shown in SEQ ID NO:5 and SEQ ID NO:6. The kit disclosed by the invention has ultra-high sensitivity and specificity on the prostate cancer, not only can be used for early diagnosis of the prostate cancer, but also can be used for identifying indolent prostate cancers and actively monitoring the progression of prostate cancer diseases.

The invention discloses a breast cancer metastasis assessment kit. The breast cancer metastasis assessment kit comprises specific fluorescent quantitative PCR detection primer pairs of total 11 target genes including BIRC5, DHCR7, UBE2C, AZGP1, IL6ST, MGP, RBBP8, STC2, CALM2, OAZ1 and RPL37A and preferably further comprises Taqman probes of the 11 target genes. By detecting the expression levels of the 11 target genes and combining pathological information such as the lymph node status and the tumor size of a breast cancer patient, the relapse and far-end metastasis risks of the breast cancer patient in 10 years can be assessed, the patient can adopt corresponding treatment measures, and excessive treatment is avoided. The kit is easy and convenient to operate, easy to interpret and low in requirement on instruments; in addition, due to the fact that a totally-closed mode is adopted in the whole PCR process, the cross contamination possibility is avoided, and then a result is more precise.

The invention discloses a system for predicting prognosis of patients with lung adenocarcinoma and judging benefit of an adjuvant chemotherapy. The system comprises a system used for detecting expression quantities of six proteins, i.e., c-Src, Cyclin E1, TTF1, p65, CHK1 and JNK1, and a protein expression quantity data processing system. The system used for detecting the expression quantities of the six proteins can determine the expression quantities of the proteins by using an immunohistochemistry staining method; the protein expression quantity data processing system converts the expression quantities of the six proteins in lung adenocarcinoma tissues, separated from to-be-predicted patients with the lung adenocarcinoma, into a prognosis score, and predicting the prognosis of the to-be-predicted patients with the lung adenocarcinoma according to the prognosis score, and / or predicting whether the to-be-predicted patients with the lung adenocarcinoma are benefited from the adjuvant chemotherapy or not according to the prognosis score.

The invention discloses liver cancer prognosis related serum miRNA markers and an application of a detection kit thereof. The tumor markers are serum miR-29a-3p and miR-192-5p which are related with human liver cancer patients. According to preliminary work, liver cancer related serum miRNA expression profiles containing miR-29a-3p and miR-192-5p and having obvious expression difference are screened out through high-throughput deep sequencing, and qPCR (quantitative polymerase chain reaction) proves and finally confirms that miR-29a-3p and miR-192-5p are liver cancer risk (prognosis) related tumor markers. The markers and detection reagents can be used for preparing the rapid-detection pPCR kit, and the kit has the characteristics of rapidness and convenience in detection, high accuracy rate, no wound and the like; a prognostic model built through combination of miR-29a-3p, miR-192-5p and BCLC stage (Barcelona clinic liver cancer stage) can be applied to classification of risk degrees of the liver cancer patients, thereby guiding individualized treatment of the liver cancer patients.

The invention relates to a breast cancer lymph node metastasis prediction method and prediction system based on a gene spectrum, and belongs to the technical field of data model prediction, and the method comprises the following steps: (1) entering a GEO platform, selecting a data set, and obtaining samples including RNA data and clinical data; (2) performing data preprocessing: dividing the obtained samples into lymph node metastasis samples and lymph node metastasis-free samples; (3) performing feature selection: selecting differential genes with differences in the lymph node metastasis samples and the lymph node metastasis-free samples, and selecting gene features by using a machine learning method; (4) performing prediction: training prediction models through at least two methods, testing the accuracy of different prediction models, and selecting the model with the highest prediction accuracy obtained by taking the differential gene obtained in the step (3) as feature input. According to the method, the TCGA database is utilized, the feature selection method with high accuracy is designed, the prediction accuracy is further improved, and the prediction accuracy can reach 97%.

The invention discloses an application of a biomarker to assessment of oral squamous cell carcinoma hazard levels. The biomarker is GSDMA and is used for detecting oral squamous cell carcinoma sampleswith different differentiation grades to discover that the biomarker presents significant differences in oral squamous cell carcinoma samples with different hazard levels, and prompt to apply the GSDMA to grading judgement of oral squamous cell carcinoma so as to instruct the doctors to adopt different treatment ways for the oral squamous cell carcinoma in different progresses and then improve the treatment effect.

The invention discloses a PCR (Polymerase Chain Reaction) specific primer and a kit for detecting a thyroid cancer metastasis associated gene, and a using method of the kit. The thyroid cancer metastasis associated gene related to PCR specific primer and the kit, which are independently researched and developed and are based on a high throughput sequencing technology, for detecting the thyroid cancer metastasis associated gene and the using method of the kit is subjected to sample validation, the PCR specific primer, the kit and the using method can be used for detecting a mutation situation of the thyroid cancer metastasis associated gene, a detection result can be used as an intermediate result together with other detecting results for judging whether cancer cells are metastasized or notor the cancer cells have the possibility of metastasis or recurrence, and an important significance in treatment and prognosis of thyroid cancer is obtained; in addition, limit of a traditional detecting technology is broken through by utilizing the high throughput sequencing technology, the detection sensitivity is increased, and even low-abundance mutant genes can also be detected, so that theimportant significance in aided prediction on spreading and recurrence of thyroid cancer cells is obtained.

The invention belongs to the technical field of tumor gene detection, and particularly relates to a gene tag for predicting breast cancer paclitaxel and anthracycline neoadjuvant chemotherapy sensitivity and application thereof. In the invention, based on LASSO logistic regression, a gene tag consisting of 25 genes related to breast cancer neoadjuvant chemotherapy sensitivity is obtained, and a score containing a gene expression quantity is calculated and predicted, so that the sensitivity of a breast cancer patient using paclitaxel and anthracycline neoadjuvant chemotherapy can be accurately predicted, the response of the patient to treatment is predicted, and whether the patient benefits from chemotherapy is discriminated, and thus selection of neoadjuvant chemotherapy regimens for breast cancer is guided, excessive treatment is avoided, and the medical cost is reduced.

The invention discloses a medical expense management method and system. The medical expense management method comprises the following steps: establishing a medical expense management database; acquiring patient information, disease information and medical information; carrying out DRG / DIP grouping on the patients; subdividing each group into one or more layers of subgroups, dividing the patients into proper subgroups, and obtaining an expense management target; and decomposing the treatment scheme, comprehensively analyzing the treatment rationality and necessity of each sub-project, and giving an analysis result of cost management and control of the treatment scheme. The medical expense management system comprises a database module, an information acquisition module and an intelligent analysis module. According to the medical expense management method and system, medical expense management is carried out based on the DRG / DIP, each item of the treatment scheme or the treatment intensity of each item is adjusted, the medical expense can be precisely managed and controlled, medical resources are reasonably distributed, diagnosis and treatment behaviors are standardized, excessive treatment is avoided, and the economic burden of a patient is relieved.

The invention discloses multifunctional moxibustion equipment which comprises a controller, a leg moxibustion sleeve, a shoulder moxibustion sleeve and a foot moxibustion sleeve. A filter is arranged on the controller, the leg moxibustion sleeve, the shoulder moxibustion sleeve and the foot moxibustion sleeve are connected with the filter by hoses, each of the leg moxibustion sleeve and the foot moxibustion sleeve comprises two symmetrical portions, each two corresponding portions are connected with each other by buckles which are arranged on the two portions, a plurality of holes are formed in certain positions of the moxibustion sleeves, the certain positions of the moxibustion sleeves correspond to the acupuncture points of a human body, moxa sticks can be inserted into the holes, a circle of sponges is arranged on the periphery of the inner side of each opening of each of the leg moxibustion sleeve, the foot moxibustion sleeve and the shoulder moxibustion sleeve, a fan is further arranged on the controller, a temperature display screen, indicator lamps and buttons are further arranged on the upper portion of the controller, the fan can be switched on and off under the control of the buttons, and the rotational speed of the fan can be controlled by the buttons. The multifunctional moxibustion equipment has the advantages that the skins of the human body can be prevented from being scalded by the multifunctional moxibustion equipment, smoke generated in moxibustion procedures can be eliminated, the multifunctional moxibustion equipment can be automatically controlled and is easy and convenient to operate, and the multiple acupuncture points of various positions of the human body can be simultaneously treated.

The invention provides an electrical stimulation system with a fatigue evaluation function. The electrical stimulation system comprises a multiplexing electrode slice, an EIM excitation current module, an FES stimulation current module, a control module and an acquisition module, and the multiplexing electrode slice is connected with the EIM excitation current module, the FES stimulation current module and the acquisition module respectively. The EIM excitation current module is used for generating an excitation current signal; the FES stimulation current module is used for generating FES stimulation signals. The electrical stimulation system has the advantages of being simple in feedback control process, stable in measurement process during resting, good in robustness and not prone to being disturbed by external factors, the amplitude of the feedback signals is large, the frequency is controllable, and preprocessing is simple. According to the scheme, on the basis of the electrical stimulation system, an EIM detection link is added, the stimulated local muscle fatigue state is fed back to the system in real time, excessive treatment caused by muscle fatigue is avoided, and the rehabilitation effect is improved.

The invention relates to a long non-coding RNA BDNF-AS and application thereof in preparing a product for diagnosing tumors or judging prognosis conditions of breast cancer treatment or judging drug resistance of breast cancer endocrine treatment or treating tumors. The BDNF-AS is taken as a marker, whether breast cancer cells in a sample are resistant to drugs and the prognosis condition of breast cancer can be judged by detecting the expression level of the BDNF-AS in the sample, so that a more effective treatment method is implemented based on a judgment result, the treatment effect is improved, and more side effects caused by blind dosage are avoided. Meanwhile, the long non-coding RNA BDNF-AS can also be used as a treatment target, and the sensitivity of endocrine treatment of the drug-resistant breast cancer to an endocrine treatment drug can be improved by knocking down the BDNF-AS, so that the treatment effect of the drug is improved; the tumor growth can be directly inhibited by singly knocking down the BDNF-AS, so that the BDNF-AS can be combined with other endocrine treatment medicines to realize a synergistic treatment effect.

The invention discloses a group of genes for molecular typing of non-hyper-mutant rectal cancer. The genes comprise an SMAD4 gene, an MUC16 gene, an FAT4 gene, an FLG gene, an ROBO2 gene and an NEB gene, molecular typing can be performed on rectal cancer according to the gene mutation characteristic combination, so that low-risk group patients with relatively low postoperative recurrence and deathrisks are screened, treatment can be performed according to a current postoperative adjuvant therapy scheme, and excessive treatment is avoided; and another group of high-risk group patients with higher postoperative recurrence and death risks can find better other schemes for the patients on the basis of the current postoperative adjuvant therapy scheme. The invention also discloses a kit for capturing the gene.

The invention relates to a method for distinguishing early and late infection of syphilis. A molecular biology gene cloning and expression technique is utilized, a syphilis TP0136 recombinant proteinis obtained, the purified syphilis TP0136 recombinant protein serves as an antigen, an ELISA method for detecting a TP0136 antibody is established, and a kit is assembled; and early and late infectionis distinguished based on the TP0136 antibody level of a syphilis infected patient, thus clinical rational drug use is advantageously guided, overtreatment is avoided, and a fast, simple and convenient detection method is provided for diagnosis and treatment of syphilis. The syphilis infection stages are distinguished by detecting the TP0136 antibody level, and the blank of a syphilis staging diagnosis and detection method is filled; and the method has the advantages of large detection flux, accurate results, high sensitivity and easy operation, and is easy to popularize at the base level.

The invention provides use of a granulocyte type myeloid derived suppressor cell in the preparation of a diagnostic biomarker for diagnosing and predicting a neoadjuvant chemosensitivity effect of muscle-invasive bladder cancer. The invention further provides use of the granulocyte type myeloid derived suppressor cell in the preparation of a kit for diagnosing and predicting the neoadjuvant chemosensitivity effect of the muscle-invasive bladder cancer. The invention further provides a kit for diagnosing and predicting the neoadjuvant chemosensitivity effect of the muscle-invasive bladder cancer. The kit contains a reagent for detecting the granulocyte type myeloid derived suppressor cell. The invention discovers the granulocyte type myeloid derived suppressor cell as a novel biomarker fordiagnosing and predicting the neoadjuvant chemosensitivity effect of the muscle-invasive bladder cancer. A muscle-invasive bladder cancer patient with low-content granulocyte type myeloid derived suppressor cells can be sequentially subjected to neoadjuvant chemosensitivity and total cystectomy operation, so that the survival rate is increased, the excessive treatment is avoided, and the operationopportunity is not delayed.

The invention discloses a human injury claim risk assessment method and a device. S1, human injury claim data are obtained; 2, classify that data of human injury claim through a data screening module;S3: Preliminary comparison between vehicle injury data and human injury data; S4: Preliminary comparison between human injury data and medical data; S5: performing integration and comparison according to the judgment information of S3 and S4, and performing judgment through the analysis module, and performing S6 if the judgment is passed, and S8 if the judgment is not passed; S6: analyzing the personnel credit of the personal injury claim data according to the preset claimant information data sample; 7, judging that analysis result of S6 by a level judging unit; S8: Risk determination information obtained by synthesizing human injury claim risk assessment methods. In a word, the method and the device of the invention have the advantages of high efficiency, accurate assessment and good safety of human injury claim risk assessment.

The invention discloses a screening kit for metastatic screening of papillary thyroid microcarcinoma and an application thereof. The kit can effectively determine whether an object is suffered from the metastatic papillary thyroid microcarcinoma or not, then the kit gives advice of early stage operation to a positive subject or allows continual observation to a negative subject. The kit avoids overtreatment and under-treatment of the papillary thyroid microcarcinoma and has excellent clinical application prospect.

The invention provides a molecular model for judging prognosis of an ovarian cancer patient and application. The molecular model comprises the steps of: comparing data of an ovarian cancer sample and data of a normal ovarian tissue sample to obtain metabolic genes with differences; shortening the range of the metabolic genes through a regression model to obtain a seven-gene combination model; and carrying out detection, verification and analysis and finally, obtaining a result that a risk score is related to the lifetime, and a patient with a high risk score has short lifetime and is poor in prognosis. Therefore, according to the invention, by constructing the molecular combination model of seven genes, prognosis of the ovarian cancer patient is evaluated, and the ovarian cancer patient who is poor in prognosis can be distinguished and selected, i.e., ovarian cancer crowds are layered, the ovarian cancer patients with high risk and poor prognosis are selected, clinicians are guided to provide more positive treatment schemes for the patients, and meanwhile, the clinicians can also be guided to avoid excessive treatment on the low-risk ovarian cancer patient.

The present invention provides a mobile terminal-based ESD preoperative discussion system, which belongs to the technical field of ESD preoperative analysis. The evaluation classification module traverses the records of patients who plan to carry out ESD surgery, and obtains the indication evaluation classification results according to the ESD indication evaluation classification standards; The preoperative discussion application module selects the medical record information of the patient who needs preoperative discussion based on the indications assessment classification results, and initiates a preoperative discussion request; the preoperative discussion participation module receives the participation request from the physician user, and if the participation request meets the corresponding medical record information operation qualification, the physician user is allowed to join the preoperative discussion and obtain the results of the ESD preoperative pathology discussion. The invention forms a mobile discussion system that is easy to run and operate, extracts relevant information from the corresponding endoscopic information system database, accurately evaluates the classification of ESD surgical indications, screens patients who meet the ESD indications, and avoids over-treatment of patients who are not suitable for endoscopic surgery. , reducing the probability of surgical complications and providing guarantee for medical safety.

The invention discloses application of an immune-related lncRNA expression profile to prediction of benefit and prognosis of adjuvant chemotherapy of small cell lung cancer. One technical scheme to be protected in the invention is application of eight lncRNAs as markers in preparation of prognosis products and / or chemotherapy benefit products for predicting small cell lung cancer patients. And the eight types of lncRNAs comprise ENOX1-AS1, AC005162, LINC00092, RPL34-AS1, AC104135, AC015971, AC126544 and AP001189, and the eight types of lncRNAs comprise the following components: ENOX1-AS1, AC005162, LINC00092, RPL34-AS1, AC104135 Experiments prove that the risk value prediction model based on the eight lncRNA gene expression profiles can effectively predict prognosis and adjuvant chemotherapy benefit of the small cell lung cancer. The invention can provide a reference basis for clinical application of chemotherapy in SCLC patients in the future, and is helpful for improving the treatment effect of clinical small cell lung cancer.

The invention discloses an application of ARRDC2 in evaluating the development process of oral squamous cell carcinoma. According to the invention, by means of high throughput sequencing and bioinformatics analysis, gene ARRDC2, which indicates significant changes in different development processes of the tumor, is screened, and ARRDC2 is suggested, as a marker molecule, to be applied to determination of the development of the oral squamous cell carcinoma, prediction of the prognosis of the tumor and guiding of therapeutic plans and curative effect monitoring.

The invention discloses a target gene for diagnosis of oral squamous cell carcinoma and application thereof. By screening genes with an expression level related to a tumor differentiation level, the expression of genes in tumor tissues in each differentiation level is determined, so that the differentiation level of a tumor is determined, thereby accurately and objectively predicting the tumor prognosis, guiding the formulation of a treatment plan and monitoring a therapeutic effect.

The invention discloses esophageal squamous carcinoma diagnosis and treatment target and application. The target is LINC01322. The fact that the LINC01322 has evident differential expression in esophageal squamous carcinoma of different differentiation levels is discovered through the high-throughput sequencing technology and bioinformatics analysis, the fact is further verified through QPCR by increasing sample quantity, and the results indicate that the LINC01322 can be used as a molecular marker for judging esophageal squamous carcinoma hazard level to guide doctors to use different treatment strategies for patients with the esophageal squamous carcinoma at different hazard levels, and medical resources are saved.

The invention discloses a screening kit for metastatic screening of papillary thyroid micro carcinoma and use thereof. The screening kit effectively determines whether or not a detection object suffers from metastatic papillary thyroid micro carcinoma, the patient of which the test result is positive is suggested with early surgery, and the patient of which the test result is negative can continueto be observed, so that excessive treatment and insufficient treatment of the papillary thyroid micro carcinoma are avoided, and the clinical application prospect is excellent.